Neo Ivy Capital Management Makes New Investment in Sotera Health (NASDAQ:SHC)

Neo Ivy Capital Management acquired a new stake in shares of Sotera Health (NASDAQ:SHC - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 43,126 shares of the company's stock, valued at approximately $720,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC purchased a new position in shares of Sotera Health during the 3rd quarter worth $32,000. CWM LLC lifted its position in Sotera Health by 86.1% during the second quarter. CWM LLC now owns 2,146 shares of the company's stock worth $25,000 after buying an additional 993 shares during the period. GAMMA Investing LLC lifted its position in Sotera Health by 125.0% during the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company's stock worth $50,000 after buying an additional 1,660 shares during the period. Capital Performance Advisors LLP acquired a new stake in Sotera Health in the 3rd quarter worth about $91,000. Finally, Point72 DIFC Ltd grew its holdings in Sotera Health by 556.6% in the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company's stock valued at $78,000 after buying an additional 5,544 shares during the period. Hedge funds and other institutional investors own 91.03% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SHC. Royal Bank of Canada reaffirmed an "outperform" rating and set a $17.00 price target on shares of Sotera Health in a research note on Thursday, November 21st. Citigroup increased their target price on Sotera Health from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group initiated coverage on Sotera Health in a research report on Friday, December 6th. They set a "neutral" rating and a $14.00 price target for the company. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $16.08.

Sotera Health Stock Performance

NASDAQ SHC traded up $0.14 during trading hours on Thursday, hitting $13.40. The company had a trading volume of 881,032 shares, compared to its average volume of 1,337,847. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The firm has a market cap of $3.80 billion, a P/E ratio of 53.04 and a beta of 1.96. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44. The business has a fifty day simple moving average of $14.71 and a 200-day simple moving average of $14.13.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. Sotera Health's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.18 EPS. Equities analysts predict that Sotera Health will post 0.61 EPS for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.